Ascendis Pharma A/S
Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets →
Analyst Sentiment
Ascendis Pharma faces potential headwinds at current valuations. Our analysis suggests 25.0% downside risk to our $186.70 target. Investors may want to consider reducing exposure or waiting for a better entry point.
The 24/7 Factor
5-Year Projection
Prediction History
| Date | Price Target | Stock Price | Rating | Upside |
|---|---|---|---|---|
| $187.74 | $253.29 | SELL | −25.9% | |
| $185.47 | $248.50 | SELL | −25.4% | |
| $251.66 | $255.41 | HOLD | −1.5% | |
| $249.24 | $243.91 | HOLD | +2.2% | |
| $249.22 | $252.66 | HOLD | −1.4% | |
| $254.06 | $259.80 | HOLD | −2.2% | |
| $258.75 | $275.43 | HOLD | −6.1% | |
| $253.25 | $274.50 | HOLD | −7.7% |
Frequently Asked Questions
What is the ASND stock price prediction for 2030?
Looking ahead to 2030, our model projects ASND could trade at an average price of $168.20, with a potential range between $126.15 and $210.25. This represents a potential 32.4% decline from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.
Is ASND a buy, sell, or hold right now?
24/7 Wall St. currently rates ASND as a SELL. Significant downside (-25.0%) Among Wall Street analysts, 18 rate it Buy, 0 rate it Hold, and 0 rate it Sell.
What is the ASND stock price target in an optimistic scenario?
In our optimistic scenario for ASND, the stock could reach $310.37 over the next 12 months, representing a 24.8% gain from today’s price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company initiatives.
What is the downside risk for ASND stock?
In our conservative scenario, ASND could trade as low as $174.26 over the next 12 months, representing a 30.0% decline from current levels. This scenario accounts for potential headwinds including earnings misses, competitive pressures, or broader market weakness.
Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →